A homozygous deletion in RPE65 in a small Sardinian family with autosomal recessive retinal dystrophy.

PURPOSE: We have been engaged in an ongoing study to screen candidate genes for mutations in small families with various forms of autosomal recessive retinal dystrophy. Here we report the screening of a cohort of 14 families from Sardinia for mutations in the genes encoding the alpha- and beta-subunits of cGMP-phosphodiesterase and RPE65 (PDE6A, PDE6B, and RPE65). METHODS: Haplotype analysis was performed on each family using simple sequence repeat markers closely flanking or within each of the three gene candidates. For families in which a gene could not be ruled out from segregating with disease, exons of the gene from proband DNAs were screened for mutations by SSCPE (single strand conformation polymorphism electrophoresis). All variants found by SSCPE were sequenced directly. RESULTS: By haplotype analysis, 6/14, 11/14, and 4/13 families were ruled out for PDE6A, PDE6B, and RPE65, respectively. A few variants were found in the proband DNAs of the remaining families, but only one was significant: a 20 bp deletion in exon 4 of RPE65. The deletion co-segregated with disease in one family and caused a frame shift that produces a stop codon downstream. It was absent from the other Sardinian families that we tested, and from Sardinian and North American controls. Results of studies of phenotype in homozygotes and heterozygotes in this Sardinian family are compared with those from a non-Sardinian family recently reported to have the same RPE65 mutation. CONCLUSIONS: This RPE65 mutation, which appears to be quite restricted in its occurrence in Sardinia, leads to childhood onset severe retinal dystrophy or Leber congenital amaurosis. Affecteds of the other 13 plus two additional families were diagnosed with arRP. This family lived in an area of Sardinia where none of the others lived suggesting different ancestral origins.

A deletion in a photoreceptor-specific nuclear receptor mRNA causes retinal degeneration in the rd7 mouse.

The rd7 mouse, an animal model for hereditary retinal degeneration, has some characteristics similar to human flecked retinal disorders. Here we report the identification of a deletion in a photoreceptor-specific nuclear receptor (mPNR) mRNA that is responsible for hereditary retinal dysplasia and degeneration in the rd7 mouse. mPNR was isolated from a pool of photoreceptor-specific cDNAs originally created by subtractive hybridization of mRNAs from normal and photoreceptorless rd mouse retinas. Localization of the gene corresponding to mPNR to mouse Chr 9 near the rd7 locus made it a candidate for the site of the rd7 mutation. Northern analysis of total RNA isolated from rd7 mouse retinas revealed no detectable signal after hybridization with the mPNR cDNA probe. However, with reverse transcription-PCR, we were able to amplify different fragments of mPNR from rd7 retinal RNA and to sequence them directly. We found a 380-nt deletion in the coding region of the rd7 mPNR message that creates a frame shift and produces a premature stop codon. This deletion accounts for more than 32% of the normal protein and eliminates a portion of the DNA-binding domain. In addition, it may result in the rapid degradation of the rd7 mPNR message by the nonsense-mediated decay pathway, preventing the synthesis of the corresponding protein. Our findings demonstrate that mPNR expression is critical for the normal development and function of the photoreceptor cells.

[Treatment methods in joint paronychia]. / Metody lecheniia sustavnogo panaritsiia.

The experience with treatment of 69 patients with articular panaritium is summarized. At stage I of the disease, a complex of conservative measures was administered. As a local treatment in most patients, puncture of a joint was employed. At stage II of the disease, the operative intervention is indicated. To enhance the effectiveness of necrosequestrectomy in articular panaritium, irradiation by means of a CO2-laser was used.

Influence of insulin and glucagon on the production of glomerulopressin by isolated rat liver.

Isolated rats livers were perfused with Krebs-Ringer-Bicarbonate (KRB) and different doses of insulin or glucagon and with insulin plus glucagon. The isolated liver of fasted rats and of rats treated with streptozotocin were perfused with (KRB). The glomerulopressin activity of the ultrafiltrate of the liver perfusates were assayed in the tonic tension contraction (TTC) of isolated stomach fundus from rats. As glomerulopressin is known to be a glucuronide, it was inactivated with beta-glucuronidase to confirm that the effect on the stomach fundus was due to the glomerulopressin and not to an autacoid. It was observed that glucagon increased the glomerulopressin activity of the perfusate and that this activity was independent of the dose of glucagon used. Insulin produced a decrease in the glomerulopressin activity of the perfusate, there being a log-dose relationship between insulin and glomerulopressin. There is a dose of insulin (1,5 X 10(-5) U/min/kg) that potentiates the response to glucagon. Fasting and treatment with streptozotocin induced an increase in the glomerulopressin activity of the perfusate. These results suggest that glomerulopressin production is influenced by glucagon and insulin, and that there is a specific ratio between these hormones that is very effective in the production of glomerulopressin.

Influence of corticoids on the production of glomerulopressin by isolated rat liver.

The isolated liver of rats treated with dexamethasone, hydrocortisone, and deoxycorticosterone acetate (DOCA) was perfused with Krebs-Ringer Bicarbonate (KRB). The liver of adrenalectomized rats was also perfused with KRB. The glomerulopressin activity of the ultrafiltrate of the liver perfusates was assayed in the tonic tension contraction (TTC) of isolated stomach fundus from rats. As glomerulopressin is known to be a glucuronide, it was inactivated with beta-glucuronidase to confirm that the effect on the stomach fundus was due to the glomerulopressin and not to an autacoid. It was observed that dexamethasone, hydrocortisone and DOCA inhibit glomerulopressin production, but adrenalectomy had no effect, therefore it can be deduced that the adrenals are not necessary for the production of glomerulopressin.

Influence of corticoids on the production of glomerulopressin by isolated rat liver.

The isolated liver of rats treated with dexamethasone, hydrocortisone, and deoxycorticosterone acetate (DOCA) was perfused with Krebs-Ringer Bicarbonate (KRB). The liver of adrenalectomized rats was also perfused with KRB. The glomerulopressin activity of the ultrafiltrate of the liver perfusates was assayed in the tonic tension contraction (TTC) of isolated stomach fundus from rats. As glomerulopressin is known to be a glucuronide, it was inactivated with beta-glucuronidase to confirm that the effect on the stomach fundus was due to the glomerulopressin and not to an autacoid. It was observed that dexamethasone, hydrocortisone and DOCA inhibit glomerulopressin production, but adrenalectomy had no effect, therefore it can be deduced that the adrenals are not necessary for the production of glomerulopressin.

Effect of glucagon and glomerulopressin on the renal function of the dog.

Glucagon was infused through the porta or through the left renal artery in dogs. Another group of dogs were infused with glomerulopressin through the left renal artery. It was observed that glucagon when infused through the portal vein enhanced the glomerulopressin production and the glomerular filtration rate (GFR). When glucagon was infused intrarenally it did not alter GRF but it had a direct tubular action decreasing sodium reabsorption in the proximal tubule. Glomerulopressin infused intrarenally increased GRF and potassium excretion. The results suggest that the increase in GFR was due to increase in glomerulopressin activity. There are three reasons for this statement: a) GRF increased when glomerulopressin activity was high, but not when there was a low activity, 5) intrarenally infused glomerulopressin produced a very significant change in the GFR of the infused kidney, while the GRF of the contralateral kidney remained unchanged and c) intrarenally administered glucagon had no effect on GFR.

Effect of glucagon on glomerulopressin production in diabetic dogs.

Glucagon (21.5 +/- 0.23 ng/min/kg) was infused through the portal vein of normal or pancreatectomized dogs. It was observed that a dose of glucagon that produces no significant change in the glycemia of normal dogs has a very small activity in the production of glomerulopressin and does not alter glomerular filtration rate (GRF). In pancreatectomized dogs this same dose of glucagon also does not alter glycemia but it induces a large increase in the production of glomerulopressin and GFR. Our results suggest that in pancreatectomized dogs glomerulopressin production is more sensitive to glucagon infusion than in normal dogs.

Effect of glucagon on glomerulopressin production in diabetic dogs

Glucagon (21.5 +/- 0.23 ng/min/kg) was infused through the portal vein of normal or pancreatectomized dogs. It was observed that a dose of glucagon that produces no significant change in the glycemia of normal dogs has a very small activity in the production of glomerulopressin and does not alter glomerular filtration rate (GRF). In pancreatectomized dogs this same dose of glucagon also does not alter glycemia but it induces a large increase in the production of glomerulopressin and GFR. Our results suggest that in pancreatectomized dogs glomerulopressin production is more sensitive to glucagon infusion than in normal dogs.

Effect of glucagon on glomerulopressin production in diabetic dogs.

Glucagon (21.5 +/- 0.23 ng/min/kg) was infused through the portal vein of normal or pancreatectomized dogs. It was observed that a dose of glucagon that produces no significant change in the glycemia of normal dogs has a very small activity in the production of glomerulopressin and does not alter glomerular filtration rate (GRF). In pancreatectomized dogs this same dose of glucagon also does not alter glycemia but it induces a large increase in the production of glomerulopressin and GFR. Our results suggest that in pancreatectomized dogs glomerulopressin production is more sensitive to glucagon infusion than in normal dogs.